Cartesian Therapeutics Q3 EPS $(1.38) Misses $(0.84) Estimate, Sales $452.000K Beat $243.500K Estimate
Benzinga Newsdesk 1 year ago
EarningsEarnings BeatsEarnings MissesNews
Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(1.38) per share which missed the analyst consensus estimate of $(0.84) by 63.31 percent. This is a 22.12 percent decrease over losses of $(1.13) per
Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(1.38) per share which missed the analyst consensus estimate of $(0.84) by 63.31 percent. This is a 22.12 percent decrease over losses of $(1.13) per share from the same period last year. The company reported quarterly sales of $452.000 thousand which beat the analyst consensus estimate of $243.500 thousand by 85.63 percent. This is a 16.80 percent increase over sales of $387.000 thousand the same period last year.